J Tang1, H Cai, L Lin, P Xie, W Zhong, M Tang. 1. Orthopedics Department, Xuhui Central Hospital, No. 966, Middle Huaihai Road, Shanghai, 200031, China.
Abstract
OBJECTIVE: As a small heavily glycosylated mucin-like glycosyl-phosphatidylinositol-anchored cell surface protein, CD24 plays an important role in carcinogenesis of various human malignancies. However, its involvement in osteosarcoma is still unclear. The aim of this study was to investigate the expression pattern and the clinical significance of CD24 in human osteosarcoma. METHODS: CD24 mRNA and protein expression levels were, respectively, detected by RT-PCR and Western blot assays using 30 pairs of osteosarcoma and noncancerous bone tissues. Then, immunohistochemistry was performed to analyze the association of CD24 expression in 166 osteosarcoma tissues with clinicopathological factors or survival of patients. RESULTS: CD24 expression at mRNA and protein levels were both significantly higher in osteosarcoma tissues than those in corresponding noncancerous bone tissues (both P < 0.001). In addition, CD24 protein was positively expressed in 129 of 166 (77.7 %) osteosarcoma specimens with a cytoplasmic and membraneous staining, and also increased in the osteosarcoma specimens with advanced clinical stage (P = 0.01) and positive distant metastasis (P = 0.005). The univariate and multivariate analyses showed that osteosarcoma patients with high CD24 expression had poorer overall and disease-free survival, and high CD24 expression was an independent prognostic factor for both overall and disease-free survival. CONCLUSION: The aforementioned findings offer convincing evidence for the first time that the increased expression of CD24 is correlated with tumor aggressiveness and tumor metastasis of osteosarcoma, and this molecule is an independent prognostic marker for osteosarcoma patients.
OBJECTIVE: As a small heavily glycosylated mucin-like glycosyl-phosphatidylinositol-anchored cell surface protein, CD24 plays an important role in carcinogenesis of various humanmalignancies. However, its involvement in osteosarcoma is still unclear. The aim of this study was to investigate the expression pattern and the clinical significance of CD24 in humanosteosarcoma. METHODS:CD24 mRNA and protein expression levels were, respectively, detected by RT-PCR and Western blot assays using 30 pairs of osteosarcoma and noncancerous bone tissues. Then, immunohistochemistry was performed to analyze the association of CD24 expression in 166 osteosarcoma tissues with clinicopathological factors or survival of patients. RESULTS:CD24 expression at mRNA and protein levels were both significantly higher in osteosarcoma tissues than those in corresponding noncancerous bone tissues (both P < 0.001). In addition, CD24 protein was positively expressed in 129 of 166 (77.7 %) osteosarcoma specimens with a cytoplasmic and membraneous staining, and also increased in the osteosarcoma specimens with advanced clinical stage (P = 0.01) and positive distant metastasis (P = 0.005). The univariate and multivariate analyses showed that osteosarcomapatients with high CD24 expression had poorer overall and disease-free survival, and high CD24 expression was an independent prognostic factor for both overall and disease-free survival. CONCLUSION: The aforementioned findings offer convincing evidence for the first time that the increased expression of CD24 is correlated with tumor aggressiveness and tumor metastasis of osteosarcoma, and this molecule is an independent prognostic marker for osteosarcomapatients.
Authors: Glen Kristiansen; Eda Machado; Niko Bretz; Christian Rupp; Klaus-Jürgen Winzer; Anne-Kathleen König; Gerhard Moldenhauer; Frederik Marmé; Julia Costa; Peter Altevogt Journal: Lab Invest Date: 2010-03-29 Impact factor: 5.662
Authors: S Aigner; Z M Sthoeger; M Fogel; E Weber; J Zarn; M Ruppert; Y Zeller; D Vestweber; R Stahel; M Sammar; P Altevogt Journal: Blood Date: 1997-05-01 Impact factor: 22.113
Authors: S Aigner; M Ruppert; M Hubbe; M Sammar; Z Sthoeger; E C Butcher; D Vestweber; P Altevogt Journal: Int Immunol Date: 1995-10 Impact factor: 4.823
Authors: Jeffrey B King; Richard J von Furstenberg; Brian J Smith; Kirk K McNaughton; Joseph A Galanko; Susan J Henning Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-06-21 Impact factor: 4.052
Authors: Praveen Polamraju; Waqar Haque; Kevin Cao; Vivek Verma; Mary Schwartz; V Suzanne Klimberg; Sandra Hatch; Polly Niravath; E Brian Butler; Bin S Teh Journal: Breast Date: 2019-10-23 Impact factor: 4.380